Novo Nordisk settles insulin pricing suit for $100M
Novo Nordisk, one of the world’s top three manufacturers of insulin, agreed to pay $100 million to settle a 2017 investor suit that alleged the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
